PF-AtlasClinical Trials › NCT03029455

A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

VX-659 · Phase 1

Registry ID
NCT03029455
Phase
Phase 1
Status
Completed
Drug / intervention
VX-659
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2016-11
Enrollment
163
Locations
10

About this trial

Evaluate the safety and tolerability of VX-659 in healthy subjects

View NCT03029455 on ClinicalTrials.gov →

Explore related

Related trials

Medical disclaimer. This page summarizes public trial data for NCT03029455 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.